Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 8/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.40 |
| ▸ | CTSD | P07339 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | BMP1 | P13497 | 1/20 | 0.40 |
| ▸ | YWHAZ | P63104 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | TASP1 | Q9H6P5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30170575 | 0.95 | OPRM1 (0.40) | KEAP1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL29485672 | 0.90 | FOLH1 (0.48) | KEAP1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL29422024 | 0.89 | BACE1 (0.51) | PTPN1CTSDBACE1YWHAZEGFR | |
| SCHEMBL30170446 | 0.89 | EGFR (0.44) | KEAP1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL30170535 | 0.88 | OPRM1 (0.42) | KEAP1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL29485686 | 0.88 | GRIN2D (0.46) | KEAP1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL30170441 | 0.86 | GLO1 (0.44) | KEAP1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL30170524 | 0.86 | GLO1 (0.44) | KEAP1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL29485627 | 0.85 | FOLH1 (0.48) | KEAP1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL30884000 | 0.85 | MME (0.43) | PTPN1CTSDBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12428446-B2 | Peptide compound or pharmaceutically acceptable salt thereof | EYEBIO KOREA (KR) | 2025-09-30 | — | — | US | disclosed |
| EP-4483959-A2 | NOVEL PEPTIDE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | EYEBIO KOREA (KR) | 2025-01-01 | — | — | EP | disclosed |
| EP-3974441-B1 | PEPTIDE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | EYEBIO KOREA (KR) | 2024-12-04 | — | — | EP | disclosed |
| US-20240352071-A1 | Novel Peptide Compound Or Pharmaceutically Acceptable Salt Thereof | EYEBIO KOREA (KR) | 2024-10-24 | — | — | US | disclosed |
| US-20240228538-A1 | Novel Peptide Compound Or Pharmaceutically Acceptable Salt Thereof | EYEBIO KOREA (KR) | 2024-07-11 | — | — | US | disclosed |
| EP-3974441-A1 | NOVEL PEPTIDE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | EYEBIO KOREA (KR) | 2022-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428446-B2 | Peptide compound or pharmaceutically acceptable salt thereof | VIP, FURIN, IAPP | KEAP1 2728/4885GRIN2D 3926/4885GRIN3B 1910/4885 |
| US-20240228538-A1 | Novel Peptide Compound Or Pharmaceutically Acceptable Salt Thereof | VIP, NPPA, NGLY1 | KEAP1 3089/4885GRIN2D 3904/4885GRIN3B 2137/4885 |
| US-20240352071-A1 | Novel Peptide Compound Or Pharmaceutically Acceptable Salt Thereof | VIP, NPPA, NGLY1 | KEAP1 3089/4885GRIN2D 3904/4885GRIN3B 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.